+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Axillary Hyperhidrosis - Pipeline Insight, 2021

  • PDF Icon

    Drug Pipelines

  • 60 Pages
  • July 2021
  • Region: Global
  • DelveInsight
  • ID: 5396952
This Axillary Hyperhidrosis - Pipeline Insight, 2021 provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Axillary Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Axillary Hyperhidrosis Understanding


Axillary Hyperhidrosis: Overview


Axillary hyperhidrosis, or excessive underarm sweating, is a common condition affecting up to 3% of the population. Axillary hyperhidrosis usually starts in childhood or adolescence but some people first experience it as adults. The impact of this condition is often underestimated - it can affect work and social situations and may cause significant psychological distress. Fortunately, effective treatments are readily available. Hyperhidrosis symptoms can range widely in their severity and impact on your life. Minor symptoms may ebb and flow over a long time. Or excessive sweating may be an everyday challenge, a constant source of frustration and insecurity.

Axillary Hyperhidrosis - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axillary Hyperhidrosis pipeline landscape is provided which includes the disease overview and Axillary Hyperhidrosis treatment guidelines. The assessment part of the report embraces, in depth Axillary Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axillary Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Axillary Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Axillary Hyperhidrosis.

Axillary Hyperhidrosis Emerging Drugs Chapters


This segment of the Axillary Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axillary Hyperhidrosis Emerging Drugs


Umeclidinium: GlaxoSmithKline

Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through the inhibition of M3 receptor at the smooth muscle leading to bronchodilation. Currently, it is in Phase II stage of development to treat Axillary Hyperhidrosis.

Meditoxin: Medytox

Meditoxin, also known as Botulinum toxin A is developed by Medytox. It is an Acetylcholine inhibitor. Currently, it is in Phase III stage of development to treat Axillary Hyperhidrosis.

Axillary Hyperhidrosis: Therapeutic Assessment


This segment of the report provides insights about the different Axillary Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Axillary Hyperhidrosis


There are approx. 3+ key companies which are developing the therapies for Axillary Hyperhidrosis. The companies which have their Axillary Hyperhidrosis drug candidates in the most advanced stage, i.e. phase II include, GlaxoSmithKline.

Phases


This report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Axillary Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intradermal
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Axillary Hyperhidrosis: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axillary Hyperhidrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axillary Hyperhidrosis drugs.

Axillary Hyperhidrosis Report Insights

  • Axillary Hyperhidrosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Axillary Hyperhidrosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Axillary Hyperhidrosis drugs?
  • How many Axillary Hyperhidrosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axillary Hyperhidrosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Axillary Hyperhidrosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Axillary Hyperhidrosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • GlaxoSmithKline
  • Medytox
  • Theravida
  • Candesant Biomedical

Key Products

  • Umeclidinium
  • Meditoxin
  • THVD-102

Table of Contents

Introduction

Executive Summary

Axillary Hyperhidrosis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

Meditoxin: Medytox
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Umeclidinium: GlaxoSmithKline
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Axillary Hyperhidrosis Key Companies

Axillary Hyperhidrosis Key Products

Axillary Hyperhidrosis- Unmet Needs

Axillary Hyperhidrosis- Market Drivers and Barriers

Axillary Hyperhidrosis- Future Perspectives and Conclusion

Axillary Hyperhidrosis Analyst Views

Axillary Hyperhidrosis Key Companies

AppendixList of Tables
Table 1 Total Products for Axillary Hyperhidrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Axillary Hyperhidrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline
  • Medytox
  • Theravida
  • Candesant Biomedical